H.C. Wainwright initiated coverage of Orchestra BioMed with a Buy rating and $14 price target. Orchestra is a clinical-stage medical device company focused on the development of novel approaches that target hypertension and artery diseases, the analyst tells investors in a research note. The firm says the company has a “de-risked” business model, enabled by partnership with established companies to drive development and commercialization.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OBIO:
- Orchestra BioMed reports Q2 EPS (45c), consensus (39c)
- Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business Update
- Orchestra BioMed Bolsters Board with Strategic Appointment
- Orchestra BioMed appoints John Mack to board of directors
- Orchestra BioMed initiated with Buy, $15 target at B. Riley
Questions or Comments about the article? Write to editor@tipranks.com